Current treatment options |
Platinum doublet chemo, pembrolizumab (PDL1 ≥ 50%), pembrolizumab + chemo. Binnenkort: atezolizumab + bevacizumab + chemo (PDL1 all comers), atezolizumab + chemo |
Therapeutic value |
No judgement |
Substantiation |
Studieresultaten: wel een verschil in PFS maar geen verschil in OS, biomarker (tumour mutational load) daarnaast nog niet mogelijk in Nederland. |
Duration of treatment |
Not found |
Frequency of administration |
1 times every 2 weeks |
Dosage per administration |
3 mg/kg |
References |
https://news.bms.com/press-release/bms/pivotal-phase-3-checkmate-227-study-demonstrates-superior-progression-free-surviva; Hellmann et al. N Engl J Med 2018; 378:2093-2104; NCT02477826 https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-opdivo-yervoy-ws/1372_en.pdf |